Showing results (521-530 of 536) with videos related to
Sort By:
Pageof 54
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.Proceedings of the National Academy of Sciences of the United States of America|June 11, 2009
Multidimensional evaluation of managed relocationDavid M Richardson, Jessica J Hellmann, Jason S McLachlan, et al.Nature Chemical Biology|June 25, 2021
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growthBianca J Lee, Jacob A Boyer, G Leslie Burnett, et al.Nature|January 8, 2025
An early precursor CD8<sup>+</sup> T cell that adapts to acute or chronic viral infectionDaniel T McManus, Rajesh M Valanparambil, Christopher B Medina, et al.Plos One|April 30, 2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional StudyCheryl A London, Heather L Gardner, Tamra Mathie, et al.Cell Reports|April 26, 2018
MIRO-1 Determines Mitochondrial Shape Transition upon GPCR Activation and Ca<sup>2+</sup> StressNeeharika Nemani, Edmund Carvalho, Dhanendra Tomar, et al.JCI Insight|October 5, 2018
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependenciesElisa Ten Hacken, Rebecca Valentin, Fara Faye D Regis, et al.Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.The British Journal of Surgery|March 14, 2026
Standards for reporting research methods, interventions, and Outcomes in Surgical Prehabilitation studies (SOS-Prehab)Chelsia Gillis, Daniel I McIsaac, Daniel Santa Mina, et al.The Journal of Biological Chemistry|June 16, 2012
Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle diseaseEloisa Carta, Seo-Kyung Chung, Victoria M James, et al.Pageof 54